About NeoGenomics
NeoGenomics is a leader in oncology diagnostics, specializing in precision medicine and genomics for cancer care. The company provides an extensive portfolio of over 500 tests covering all major testing modalities, including single-gene molecular testing, immunohistochemistry (IHC), flow cytometry, fluorescence in situ hybridization (FISH), DNA- and RNA-based next-generation sequencing (NGS), and comprehensive genomic profiling (CGP). NeoGenomics serves three primary markets: healthcare providers seeking precision oncology testing to support personalized patient care, biopharma partners developing cancer therapies and conducting clinical trials, and patients navigating their cancer treatment journey. The company's testing solutions span solid tumors and hematologic cancers, offering advanced tissue-based, liquid biopsy, and hematology tests. Key product lines include the PanTracer portfolio for comprehensive genomic profiling, RaDaR ST for minimal residual disease detection with sensitivity down to 1 part per million, and disease-specific panels for lung, breast, colorectal, gastric, gynecologic, and hematologic cancers. NeoGenomics maintains a database of over 2 million patient profiles from more than 40,000 unique providers across 4,000 healthcare organizations, providing oncology data solutions that deliver insights across the cancer care continuum. The company's mission centers on advancing personalized cancer care through scientific excellence, integrated solutions, and meaningful impact throughout the patient treatment journey.
Mission & Story
Mission
Advancing personalized cancer care through scientific excellence, integrated solutions, and meaningful impact across the cancer care continuum
Clinical Focus
Medical conditions and clinical areas addressed by NeoGenomics.
Who It Serves
Milestones & Awards
Recent Milestones
Unveiled new mission, vision, and tagline reflecting strengthened commitment to personalized cancer care. Launched RaDaR ST MRD detection technology. Introduced PanTracer Pro comprehensive testing solution combining CGP with IHC and ancillary testing.
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.